Rabies Vaccine
Rabies Vaccine - Related Videos
04:10
A Trap-Vaccinate-Release Protocol for Immunization of Skunks and Additional Rabies Vectors Against Rabies
0 Views •
2024
Here, we present a protocol to demonstrate safe, trap-vaccinate-release (TVR) techniques for carnivores susceptible to rabies.
09:04
In Vitro ELISA Test to Evaluate Rabies Vaccine Potency
0 Views •
Cited by 5 •
2020
Here we describe an indirect ELISA sandwich immunocapture to determine the immunogenic glycoprotein contents in rabies vaccines. This test uses a neutralizing Monoclonal Antibody (mAb-D1) recognizing glycoprotein trimers. It is an alternative to the in vivo NIH test to follow the consistency of vaccine potency during production.
05:42
Using a Sandwich ELISA to Determine the Immunogenic Glycoprotein Content in a Vaccine
0 Views •
2025
This video showcases an indirect enzyme-linked immunosorbent assay or ELISA sandwich immunocapture assay designed to assess immunogenic glycoprotein levels in vaccines. The assay plate, containing glycoprotein-specific antibodies, is incubated with serially diluted vaccine samples, including reference and test vaccines, followed by immunoassay to quantify glycoprotein content in the test vaccine.
06:56
Rabies Necropsy Techniques in Large and Small Animals
0 Views •
Cited by 2 •
2019
The goal of this protocol is to demonstrate safe necropsy techniques in small and large animals to obtain satisfactory tissue samples for rabies testing.
07:54
Detection of Rabies IgG and IgM Antibodies Using the Rabies Indirect Fluorescent Antibody Test
0 Views •
2024
The aim of this manuscript is to examine the use of the rabies indirect fluorescent antibody test for the detection of rabies-specific IgG and IgM antibodies.
FAQs
Vaccination prompts the immune system to produce neutralizing antibodies, which can act against rabies virus, while also establishing immune memory. This combination supports a prepared response rather than relying only on defenses after infection has begun. Its importance is greatest when the immune response develops before viral spread reaches the central nervous system.
The vaccine uses inactivated rabies virus components, allowing them to stimulate immune recognition without causing rabies disease. This design separates exposure to the signals needed for antibody and memory formation from exposure to a disease-causing virus. As a result, immunization can support prevention while maintaining the intended safety feature of noninfectious vaccine material.
Timing matters because rabies can spread from an exposure toward the central nervous system. Vaccination is most useful as part of prevention while this progression can still be interrupted. A delayed response may reduce the opportunity to establish protection before the virus reaches nervous tissue, which explains why post-exposure action is treated as time-sensitive.
Before exposure, vaccination is used for people whose occupations or travel may place them at increased risk. After exposure, it becomes part of post-exposure prophylaxis, a prevention strategy used following a possible contact with the virus. These settings reflect different risk-management points: preparation in advance versus intervention intended to prevent progression after exposure.
Post-exposure prophylaxis includes rabies vaccination together with prompt wound cleansing. Rabies immunoglobulin is also included when indicated. Combining these measures addresses the exposure through local wound care and immune-based prevention rather than relying on vaccination alone. The overview identifies this coordinated approach as a critical way to interrupt viral spread before nervous-system involvement.
Pre-exposure vaccination is intended for people with occupational or travel-related risk of encountering rabies. Its purpose is to establish immune preparation before a possible exposure occurs, rather than waiting until a bite or other contact creates an urgent prevention need. This application supports individual protection and contributes to broader infection-prevention efforts.